VACCITECH PLC. launches an IPO.

IPO of VACCITECH PLC. (VACC) will take place on April 29, 2021. VACCITECH is a clinical stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company has a broad pipeline of clinical and preclinical therapeutic and prophylactic programs at both clinical and preclinical stages. Its current therapeutic programs include VTP-300 to treat chronic hepatitis B infection, VTP-200 to treat human papilloma virus infection, VTP-850 o treat prostate cancer and VTP-600 to treat non-small cell lung cancer. Besides, the company together with Oxford University invented  the COVID-19 candidate vaccine and assigned it to facilitate the following transfer of vaccine rights to AstraZeneca. This vaccine is now known as COVID-19 Vaccine AstraZeneca. 

The estimated valuation of the company after its IPO will be $314 million.

The listed IPO bookrunners are Morgan Stanley, Jefferies, Barclays, William Blair and H.C. Wainwright & Co.